Sanofi Sues Mylan Over EpiPen Marketing

(RTTNews) - Sanofi has filed a lawsuit against Mylan alleging that the company violated antitrust law by taking several steps to thwart any generic competition for EpiPen.

According to the lawsuit, Sanofi claims that Mylan allegedly offered "new and unprecedented" discounts off the list price of the EpiPen to prevent various players, including health insurers, from covering the Auvi-Q.

EpiPen is an epinephrine injection used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. Sanofi had earlier tried to launch a rival for EpiPen Auvi-Q. However, the product is now being sold by pharmaceutical company Kaleo, after Sanofi withdrew its product in 2015.

Sanofi says that by acting improperly Mylan artificially raised Sanofi's costs to market Auvi-Q, as well as the cost for patients to buy the device.

Sanofi wants Mylan to pay for the "hundreds of millions of dollars in sales" it los from their actions as well as other costs. The company is asking for triple the amount in damages along with legal fees.